Skip to main content
Equibles
ELVN logo

ELVN · Enliven Therapeutics, Inc.

Track ELVN — free

Use ELVN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ELVN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$54.32 -1.91 (-3.40%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$3.98B
Shares
73.27M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$54.32 Open$57.00 Day$54.12–57.00 52W close$15.14–61.15 Avg vol 30d1.0M Short int8.6M · 11.7% float · 11.1d Short vol33% Last earningsMay 27, 2026 DataMar 2020–Sep 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Apr 4, 2027 Est · unconfirmed · in 29 wks
Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$105.93M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$895.15M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+27.0%
Year over year · more shares
Price change (1Y)
+172.7%
Trailing year
Short interest
11.7%
Latest settlement · 11.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +42%
above
Price vs 50-day avg −3%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 85%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −6%
trailing
6-month return +87%
trailing
YTD return +253%
this year
Relative strength +69%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $56 › 200d $38 — 50d above 200d
Institutional flow Accumulating
+23% holders QoQ · +61 funds added
Insider flow Distributing
Net -$51.7M over 90 days · 100% sells
Short interest Rising
11.74% of float · ▲ +4.1% MoM · 11.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
214 holders — near 3-yr high, broad support
Squeeze score 78
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 80%
annualized · 1-yr
Max drawdown −37%
past year
ATR 4.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+42% Bullish
Price vs 50-day avg
−3% Neutral
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
85% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $56 › 200d $38 — 50d above 200d
Institutional flow Accumulating
+23% holders QoQ · +61 funds added
Insider flow Distributing
Net -$51.7M over 90 days · 100% sells
Short interest Rising
11.74% of float · ▲ +4.1% MoM · 11.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
214 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $15 Now $54 · 85% Range high $61
vs 200-day avg +42% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ELVN
Enliven Therapeutics, Inc.
this stock
$3.98B +252.7% — — 11.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.67B +1.2% +20.8% 19.6 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
CSLLY
Csl Ltd
 $57.41B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
214
% held
109.8%
Net QoQ
+16.4M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
209
View
Short & Settlement
Short Interest Rising
Shares short
8.6M
Days to cover
11.1d
Change
+341.3K sh
View
Short Volume
Short vol %
33%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
1.4K
Value
$84.7K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
54.6%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$51.7M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-103.7M
EPS diluted
$-1.83
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
12
View
Proposed Sales
Value
$2.3M
Shares
38.0K
Filed
Sep 4, 2026
View
Exempt Offerings
Offering
$90.0M
Filed
Apr 3, 2024
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
ELVN -8.9% -6.4% +87.1% -6.2% +252.7%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -7.8% -4.7% +69.3% -5.8% +240.7%
Key facts CIK 1672619 CUSIP 29337E102 13F (30d) 135 filings 135 filers Visit website Investor relations